Diffuse Esophageal Spasm: Calcium Channel Blocker, PDE-5 Inhibitor, or Botulinum Toxin
Manometry-confirmed hypercontractile esophagus leaves the team choosing among three real options — a calcium channel blocker, a PDE-5 inhibitor borrowed from an entirely different indication, and endoscopic botulinum toxin — none backed by strong trial-level evidence, all resting on genuinely differing mechanistic logic.
Curtis A., 52, restores vintage motorcycles in his garage most evenings after his shift managing a warehouse floor, and it was mid-restoration, mid-argument with himself over a stuck bolt, that he first felt what he describes as a “vise” closing across his chest — frightening enough that his wife drove him to an emergency department, where a cardiac workup was entirely negative. He's had similar episodes intermittently for over a year, sometimes with swallowing, sometimes not, lasting minutes at a time and occasionally severe enough to stop him mid-task. High-resolution manometry showed simultaneous, high-amplitude contractions (distal contractile integral values well above the hypercontractile threshold) without the characteristic esophagogastric junction outflow obstruction pattern that would point toward achalasia instead.
None of the three real pharmacologic options here rests on strong trial evidence — this is a genuinely thin literature by the site's own honest accounting, not a case where the team is choosing between a well-studied first-line agent and lesser alternatives. Calcium channel blockers have the longest track record and the most direct mechanistic logic (reducing smooth-muscle contractile force), but Davies and colleagues' early trial of nifedipine found only modest, inconsistent symptom benefit despite a genuine drop in contraction amplitude. PDE-5 inhibitors, borrowed entirely from erectile-dysfunction and pulmonary-hypertension indications, potentiate nitric-oxide-mediated smooth-muscle relaxation; Shafiee and colleagues' 2023 systematic review found real reductions in LES pressure and contraction amplitude across the small trials pooled, an off-label use with real but limited supporting data on whether that translates to symptom relief. Botulinum toxin, injected at multiple sites along the distal esophageal body rather than just the LES the way it's used in achalasia, has case-series-level support for reducing spasm frequency but requires repeat endoscopic procedures as the effect wanes. None of the three fixes the deeper problem. DES and hypercontractile esophagus, unlike achalasia, don't reliably correlate symptom severity with manometric contraction amplitude, which is part of why even a technically successful pharmacologic reduction in contractile force doesn't always translate cleanly into how much relief a given patient actually reports feeling. Curtis was told directly that whichever oral agent he chose was, honestly, closer to a coin flip between two thin evidence bases than a confident recommendation — language the team felt he deserved given how often "we recommend X" gets said with more certainty than the underlying literature in this specific disorder actually supports.
Three thin evidence bases, one real decision to make
I'd start with a calcium channel blocker. It has the most direct mechanistic logic here — reducing the contractile force behind exactly what his manometry is showing — and the longest clinical track record of the three real options, even though I want to be honest that the trial evidence behind it is modest and genuinely inconsistent across the small studies that exist.
I'd actually reach for a PDE-5 inhibitor first instead. It's borrowed entirely from erectile-dysfunction and pulmonary-hypertension indications, so this is genuinely off-label use, but there's real case-series data specifically in hypercontractile and spastic esophageal disorders — not just an extrapolated mechanism.
I'd also weigh the side-effect profile against who he is: he's on his feet managing a warehouse floor and working on motorcycles most evenings, and a CCB's hypotension and peripheral edema risk is a more disruptive cost for him than a PDE-5 inhibitor's headache and flushing.
Since neither option has strong trial backing, I don't think this needs to be a hard disagreement — either is a reasonable first try, and I'd let his own tolerance of hypotension versus headache help decide it once we've named both plainly. What I want on record either way is that botulinum toxin isn't a fallback we're vaguely gesturing at if oral therapy fails — it's a real, named next step with its own case-series support, just reserved for now given the procedural burden of repeat endoscopic dosing.
Agreed: a 4-week trial of diltiazem ER, Curtis's own choice once both oral options' side-effect profiles were explained plainly against his daily physical routine, with a symptom diary to judge response objectively rather than by recall alone at the follow-up visit.
Switch to a PDE-5 inhibitor trial next, rather than escalating straight to an endoscopic procedure while an equally-thin-evidence oral option remains untried.
Botulinum toxin injection becomes the next step, already named and planned for rather than requiring a fresh conversation at that point.